- Net income for Torrent Pharma in the first quarter of 2024 was 4.57 billion rupees, a 21% increase year-over-year (y/y) and close to the estimated 4.61 billion rupees.
- Revenue reached 28.59 billion rupees, growing by 10% y/y, though it fell short of the 28.78 billion rupees estimate.
- Domestic sales were 15.35 billion rupees, a 7.3% increase y/y, but slightly below the estimate of 15.63 billion rupees.
- US revenue declined by 12% y/y to 2.59 billion rupees, missing the estimate of 2.8 billion rupees.
- Revenue from Brazil was 1.96 billion rupees, up 3.2% y/y but below the 2.6 billion rupees estimate.
- Germany revenue matched the estimate, reaching 2.84 billion rupees, an increase of 10% y/y.
- Total costs stood at 22.27 billion rupees, a 6.6% increase from the previous year.
- Research and Development (R&D) expenses were 1.35 billion rupees, up 4.7% y/y and close to the estimated 1.39 billion rupees.
- EBITDA was 9.04 billion rupees, up 14% y/y, slightly below the estimate of 9.09 billion rupees.
- Gross margin improved to 75.7% from 75% y/y, exceeding the estimate of 74.2%.
- Shares of Torrent Pharma rose 3.6% to 3,139 rupees with 585,410 shares traded.
- Analyst ratings included 28 buys, 5 holds, and 2 sells.
A look at Torrent Pharmaceuticals Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Looking at Torrent Pharmaceuticals‘ overall outlook utilizing the Smartkarma Smart Scores, the company has received varying ratings across different factors. With a moderately positive score in Value from Smartkarma, Torrent Pharmaceuticals is seen as having potential for investment at a reasonable price. Its Dividend score stands strong at 4, indicating a solid plan for distributing profits to shareholders. In terms of Growth and Resilience, Torrent Pharmaceuticals has received scores of 3, showing moderate prospects for expansion and ability to withstand market challenges. Moreover, the company’s Momentum score of 4 suggests a strong performance trend that investors may find appealing.
Overall, Torrent Pharmaceuticals Ltd. manufactures bulk drugs and pharmaceutical formulations with a wide range of products in its portfolio. Specializing in cardio-vascular, psychotropic, and anti-biotic drugs, the company also produces bulk drugs such as atenolol, ciprofloxacin, and norfloxacin. Additionally, Torrent Pharmaceuticals has wholly owned subsidiaries operating in various regulated and less regulated international markets, driving its global presence and potential for future growth.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
